Evidence map›Paper›PMID 41452939›Full record

ArticlePLoS pathogens2025

Cyclic-di-GMP controls Type III effector export and symptom development in Pseudomonas syringae infections via the export ATPase HrcN.

Danny Ward, Richard H Little, Catriona M A Thompson, Jacob G Malone

Abstract read
In one paragraph

Article in PLoS pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Danny WardJohn Innes Centre, Norwich Research Park, Norwich, United Kingdom.
Richard H LittleJohn Innes Centre, Norwich Research Park, Norwich, United Kingdom.
Catriona M A ThompsonJohn Innes Centre, Norwich Research Park, Norwich, United Kingdom.
Jacob G MaloneJohn Innes Centre, Norwich Research Park, Norwich, United Kingdom.ORCID 0000-0003-1959-6820

Funding

BBSRC BB/J014524/1Biotechnology and Biological Sciences Research Council (BBSRC) BBS/E/J/000PR9797Biotechnology and Biological Sciences Research Council (BBSRC) BB/X010996/1
6 · The paper itself

Abstract

Pseudomonas syringae is a destructive bacterial pathogen that infects a wide variety of plants. Following apoplastic entry, P. syringae uses its type 3 injectisome (T3I) to secrete host-specific effectors into the cytoplasm, enabling tissue wetting and immune suppression and leading to bacterial proliferation, chlorosis and necrosis. P. syringae strains encode dozens of highly specialised effectors, whose composition defines strain specificity and host range. Effective plant infection depends on the tight temporal and hierarchical control of effector delivery through the T3I. Effector secretion is driven by HrcN, an ATPase complex that interacts with the base of the T3I and is essential for plant infection. HrcN binds specifically to the bacterial signalling molecule cyclic-di-GMP, although the impact of binding on T3I function and P. syringae virulence is currently unknown. To address this, we examined the influence of mutating the predicted cyclic-di-GMP-hrcN binding site on plant infection and effector secretion. Despite maintaining effective bacterial proliferation in Arabidopsis thaliana leaves, two hrcN mutants showed severely compromised disease symptoms, a phenotype linked to reduced translocation of a specific subset of T3I-effectors, with HopAA1-2 particularly important for symptom development. We propose that cyclic-di-GMP binding may represent a novel regulatory mechanism for effector secretion during bacterial infections.

Indexed as

Adenosine TriphosphatasesBacterial ProteinsCyclic GMPPlant DiseasesPseudomonas InfectionsPseudomonas syringaeArabidopsisVirulenceAdenosine TriphosphatasesBacterial Proteinsbis(3',5')-cyclic diguanylic acidCyclic GMP

Identifiers

PMID41452939
PMCPMC12774368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.